We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

146 hedge funds and large institutions have $897M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

44% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 41

29% more call options, than puts

Call options by funds: $576K | Put options by funds: $446K

14% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 22

7% more capital invested

Capital invested by funds: $839M → $897M (+$57.7M)

2% more funds holding

Funds holding: 143146 (+3)

Holders
146
Holders Change
+3
Holders Change %
+2.1%
% of All Funds
2.33%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
25
Increased
59
Reduced
41
Closed
22
Calls
$576K
Puts
$446K
Net Calls
+$130K
Net Calls Change
-$4.48M
Name Holding Trade Value Shares
Change
Change in
Stake
RG
1
Redmile Group
California
$86.2M +$33.2M +1,988,788 +55%
BlackRock
2
BlackRock
New York
$85.7M +$2.09M +124,963 +2%
DM
3
Deerfield Management
New York
$80.6M +$47.9M +2,869,410 +122%
Vanguard Group
4
Vanguard Group
Pennsylvania
$71.2M -$2.24M -134,231 -3%
AC
5
Armistice Capital
New York
$63.3M -$17.9M -1,072,000 -21%
State Street
6
State Street
Massachusetts
$51.3M -$2.1M -125,874 -4%
B
7
Braidwell
Connecticut
$50.1M -$504K -30,162 -0.9%
Goldman Sachs
8
Goldman Sachs
New York
$47.2M +$14.3M +857,540 +39%
PCH
9
Polar Capital Holdings
United Kingdom
$27M +$8.35M +500,000 +40%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$21.2M +$4.93M +294,987 +27%
DTC
11
Deep Track Capital
Connecticut
$21.1M +$22.8M +1,363,201 New
N
12
Nuveen
North Carolina
$20.4M +$7.52M +450,516 +52%
NLVP
13
New Leaf Venture Partners
New York
$18.7M
JFG
14
Jefferies Financial Group
New York
$18.2M +$16.7M +1,000,000 +571%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$16.5M +$2.58M +154,710 +17%
Morgan Stanley
16
Morgan Stanley
New York
$14.4M +$5.42M +324,538 +53%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$13.6M -$5.71M -341,943 -28%
Assenagon Asset Management
18
Assenagon Asset Management
Luxembourg
$13.1M -$2.8M -167,447 -16%
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$12.2M -$3.47M -207,707 -21%
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$9.27M -$421K -25,212 -4%
Northern Trust
21
Northern Trust
Illinois
$7.81M +$1.08M +64,805 +15%
PHP
22
Parkman Healthcare Partners
Connecticut
$7.6M +$2.45M +146,852 +43%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$7.35M +$937K +56,100 +13%
Charles Schwab
24
Charles Schwab
California
$7.06M +$1.62M +96,827 +27%
ECM
25
ExodusPoint Capital Management
New York
$6.72M -$2.42M -144,984 -25%

DCPH Hedge Fund Activity: Q1 2023 in Review

146 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2023, worth a combined $897M — up 6.9% from $839M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new DCPH positions and 22 closed out — a net gain of 3 holders — while 59 added to existing stakes and 41 trimmed.

The largest buyer was Deerfield Management, adding an estimated $47.9M. The largest seller was Wolverine Trading, exiting entirely with an estimated $28.7M sold.

  • 146 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2023, up from 143 in Q4 2022.
  • Funds reported $897M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2023, up 6.9% quarter-over-quarter.
  • 25 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 22 closed out, a net change of +3 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Deerfield Management, an estimated $47.9M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Wolverine Trading, an estimated $28.7M sold.

Based on aggregated 13F filings for Q1 2023.